Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stomach cancer drug combo shows promise in new trial

NCT ID NCT04882241

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps Chinese adults with stomach or gastroesophageal junction cancer. Participants received the drug combination or a placebo before and after surgery. The goal was to see if the combination improves outcomes like preventing cancer from returning.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

120 people

The number who actually took part.

Started

Jul 2020

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has previously untreated localized gastric or gastroesophageal junction (GEJ) adenocarcinoma as defined by T3 or greater primary lesion or the presence of any positive nodes - N+ (clinical nodes) without evidence of metastatic disease. * Plans to proceed to surgery following pre-operative chemotherapy based on standard staging studies per local practice. * Is willing to provide tissue from a tumor lesion at baseline and at time of surgery. * Has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1 within 3 days prior to the first dose of study treatment. * Has adequate organ function. * Male participants of childbearing potential must agree to use an adequate method of contraception for the course of the study through 180 days after the last dose of chemotherapy. * Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is greater. * Has life expectancy of greater than 6 months. Exclusion Criteria: * Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis. * Has an active infection requiring systemic therapy. * Is currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. * Has received prior therapy with an anti-programmed cell death protein-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (i.e., cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\], tumor necrosis factor receptor superfamily member 4 \[OX-40\], necrosis factor receptor superfamily member 9 \[CD137\]) or has previously participated in a MSD pembrolizumab (MK-3475) clinical study. * Has received prior systemic anti-cancer therapy including investigational agents for the current malignancy. * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior the first dose of study treatment. * Has a known additional malignancy that is progressing or has required active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that have undergone potentially curative therapy are not excluded. * Has a known severe hypersensitivity (≥ Grade 3) to pembrolizumab, its active substance and/or any of its excipients, or to any of the study chemotherapy agents and/or to any of their excipients. * Has an active autoimmune disease that has required systemic treatment in past 2 years. * Has a known history of human immunodeficiency virus (HIV) infection. * Has a known history of Hepatitis B or known active Hepatitis C virus infection. * Has a known history of active tuberculosis (TB). * Female participants who are pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the screening visit through180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is greater. * Male participants who are expecting to father children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of chemotherapy. * Has had an allogenic tissue/solid organ transplant. * Has received a live vaccine within 30 days prior to the first dose of study treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer Gastroesophageal junction cancer

Contacts and locations

Locations

  • Afflilated Hospital of Bengbu Medical College-Surgical Oncology (Site 0638)

    Bengbu, Anhui, 233004, China

  • Beijing Cancer Hospital ( Site 0221)

    Beijing, Beijing Municipality, 100142, China

  • Beijing Friendship Hospital ( Site 0637)

    Beijing, Beijing Municipality, 100050, China

  • Fourth Hospital of Hebei Medical University ( Site 0633)

    Shijiazhuang, Hebei, 050035, China

  • Fujian Medical University Union Hospital-1 Bingfanglou-Gastric Surgery Department (Site 0632)

    Fuzhou Fujian, Fujian, 350001, China

  • Fujian Provincial Cancer Hospital ( Site 0230)

    Fuzhou, Fujian, 350014, China

  • Henan Cancer Hospital (Site 0227)

    Zhengzhou, Henan, 450008, China

  • Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 0642)

    Shanghai, Shanghai Municipality, 200127, China

  • Shandong Provincial Hospital-Gastrointestinal Surgery ( Site 0640)

    Jinan, Shandong, 250001, China

  • Sichuan Cancer hospital

    Chengdu, Sichuan, 610041, China

  • Sir Run Run Shaw Hospital ( Site 0233)

    Hangzhou, Zhejiang, 430030, China

  • Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army ( Site 0647)

    Xi'an, Shaanxi, 710038, China

  • The Affiliated Hospital of Qingdao University ( Site 0636)

    Qingdao, Shandong, 266003, China

  • The Affiliated Hospital of Xuzhou Medical College-Oncology ( Site 0645)

    Xuzhou, Jiangsu, 221006, China

  • The First Affiliated Hospital of Guangzhou Medical University ( Site 0224)

    Guangzhou, Guangdong, 510120, China

  • The First Affiliated Hospital of Wenzhou Medical University (Site 0652)

    Wenzhou, Zhejiang, 32500, China

  • The First Affiliated Hospital, Sun Yat-sen University (Site 0635)

    Guangzhou, Guangdong, 510080, China

  • The First Hospital of Jilin University-Gastrointestinal Surgery ( Site 0234)

    Changchun, Jilin, 130021, China

  • Zhejiang Cancer Hospital ( Site 0231)

    Hangzhou, Zhejiang, 310022, China

  • Zhejiang Provincial People's Hospital-Oncology (Site 0656)

    Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.